Genomic Vision Launches HexaCard, a New Service for Characterizing Transformed Cell Lines
18 July 2023 - 3:00PM
Business Wire
- HexaCard is an innovative service for improving quality
control in cell characterization for biomanufacturing, and cell and
gene therapy applications
- HexaCard offers a highly accurate analytical method for
characterizing transformed cell lines, with the ability to assess
six critical parameters in a single assay
- HexaCard allows identification of transgene stability, cell
clonality and provides a unique genetic ID card for each clone or
batch, ensuring the accuracy of the entire production
pipeline
Regulatory News:
Genomic Vision (FR0011799907 – GV, – the “Company”), a
Euronext-listed biotechnology company that develops products and
services for the highly accurate characterization of DNA sequences,
is pleased to announce the launch of its new service, HexaCard.
HexaCard is an application of Genomic Vision's proprietary
Molecular Combing Technology (MCT) that offers precise
visualization and measurement of individual DNA molecules. HexaCard
aims to consolidate multiple technologies used in assessing
engineered genome modifications, offering a streamlined,
one-stop-shop solution for the cell and gene therapy (CGT), and
biomanufacturing industries. By combining six analytical parameters
into a single assay, Genomic Vision's HexaCard service offers a
range of advantages in bioproduction and CGT applications.
The six analytical parameters assessed by HexaCard encompass
crucial aspects of cell line characterization. These parameters
include determining copy number, assessing orientation, identifying
integration sites, evaluating genetic integrity in the target
region, analyzing on/off target insertions, and establishing a
genetic signature for stability assessment. This comprehensive
analysis ensures the selection of the most suitable clones,
enhancing productivity and stability while reducing turnaround time
and costs.
With HexaCard, researchers and biomanufacturers can confidently
optimize their processes, make informed decisions, and mitigate the
risks associated with non-competent cell line development. By
enabling the identification of transgene stability, clonality and
providing a unique genetic ID card for each clone or batch,
HexaCard ensures the accuracy of the entire production
pipeline.
This state-of-the-art service addresses the unmet need to
accurately characterize genetic construct of transformed cell, the
prevalent issues of misidentified cell lines and cellular
cross-contamination. This technology, coupled with the Company’s
AI-based analysis software, FiberSmart®, generates comprehensive
data and insights that facilitates quantitative decision-making
capabilities. HexaCard forms part of Genomic Visions’ broader suite
of complementary tools to safely accelerate development time,
reduce cost of bioproduction & cell and gene therapies.
Today’s announcement is further execution of the Company’s
refocused strategy in the Bioproduction and CGT arenas. Addressing
a c.$5 Billion market opportunity Genomic Vision is well positioned
for growth with a clear strategic roadmap in place to expand its
core offering and capitalize on the increasing demand for targeted
advanced therapies in high-growth industries.
Florent Pestelle, Chief Operating Officer of Genomic Vision,
said: "Genomic Vision's HexaCard service empowers researchers
and biomanufacturers with a groundbreaking solution to overcome the
challenges of cell line characterization. By providing an accurate
genetic ID card for each clone or batch, we eliminate the risks
associated with cellular cross-contamination and misidentification.
This allows our customers to boost productivity, ensure stability,
and ultimately deliver high-quality products, while reducing both
turnaround time and costs.”
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company that develops products
and services for the highly accurate characterization of genome
modifications. We deliver high-quality integrated genomic analysis
solutions to improve quality control and bioproduction standards of
advanced gene therapies at scale. Based on molecular combing
technology and artificial intelligence, The Company provides robust
quantitative measurements needed for high confidence
characterization of transformed cell lines and prediction of cell
line performance, in particular in the context of the
biomanufacturing processes of cell and gene therapies. Genomic
Vision’s molecular combing technology has further applications in
drug development of agents targeting DNA replication and damage
response mechanisms, visualizing DNA replication kinetics and
telomere length maintenance. Genomic Vision, based near Paris in
Bagneux, is a public company listed in compartment C of Euronext’s
regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
Member of the CAC® Mid & Small and CAC® All-Tradable
indices
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the universal
registration document filed with the AMF on April 28, 2023 under
number D.23-0383, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
Genomic Vision has set up a financing line in the form of
convertible notes with warrants (OCABSA) with its Financing
partner.
The shares resulting from the conversion or exercise of the
aforementioned securities will, in general, be sold on the market,
which could create downward pressure on the share price as well as
a dilution.
Shareholders could therefore suffer a loss of their invested
capital due to a significant decrease in the value of the company's
shares. The company has carried out several dilutive financing
operations, and investors are advised to be very careful before
making a decision to invest in the company's securities.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230717938314/en/
Genomic Vision Aaron Bensimon Chairman of the Management
Board Tel.: +33 1 49 08 07 51 investisseurs@genomicvision.com
Ulysse Communication Media Relations Bruno Arabian Tél.: +33
1 42 68 29 70 barabian@ulysse-communication.com
Consilium Strategic Communications International Investor
Relations & Strategic Communications Tel.: +44 (0) 20 3709 5700
GenomicVision@consilium-comms.com
NewCap France Investor Relations & Strategic
Communications Tel.: +33 1 44 71 94 94 gv@newcap.eu
Guerrero Ventures (TSXV:GV)
Historical Stock Chart
From Apr 2024 to May 2024
Guerrero Ventures (TSXV:GV)
Historical Stock Chart
From May 2023 to May 2024